Holen Sie sich die Stockscreener-App
5.08
9.84%
0.455
Cns Pharmaceuticals Inc Aktie (CNSP) Neueste Nachrichten
CNSP: Cns Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
With 45.72% of shares represented, CNS Pharmaceuticals (CNSP) wins approval to expand its stock plan. - Stock Titan
CNS Pharmaceuticals, Inc.Common Stock (NQ: CNSP - The Chronicle-Journal
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company - globenewswire.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
CNS Pharmaceuticals (CNSP) Outlines Strategic Shift Amid Unprofi - GuruFocus
A biotech is seeking cancer or brain therapies. CNS Pharmaceuticals lays out its plan. - Stock Titan
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference - Weatherford Democrat
CNS Pharmaceuticals CEO highlights new leadership team and strategy - Stock Titan
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com South Africa
Vertical Data: Downs Most Recently Served as CFO of CNS Pharmaceuticals >VDTA - Moomoo
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock - Investing.com
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com Canada
CNS Pharmaceuticals (CNSP) director buys 2,000 shares in open-market trade - Stock Titan
CNS Pharmaceuticals (CNSP) CEO converts 4,750 RSUs to stock - Stock Titan
CNS Pharmaceuticals (CNSP) lists director Michal with no reported trades - Stock Titan
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com UK
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com India
Vertical Data Appoints Chris Downs as Interim Chief Financial Officer - Yahoo Finance
Central Nervous System (CNS) Lymphoma Market Outlook Signals Expansion To $2.08 Billion Through 2030 - openPR.com
CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesSwing Trade Setups - vinanet.vn
CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesSwing Entry Signals - dars.gov.et
CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesHead and Shoulders - dars.gov.et
Ikarian Capital (CNSP) discloses 9.9% beneficial ownership in CNS Pharmaceuticals - Stock Titan
CNSP Q2 2026 Earnings: Wider-than-Expected Loss of -$0.38 per Share Amid Clinical-Stage OperationsNet Profit Margin - vinanet.vn
CNS Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
CNS PHARMACEUTICALS ($CNSP) Releases Q2 2026 Earnings - Moomoo
CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - TradingView
CNSP: Accelerated transformation and strong cash position support pipeline expansion and strategic growth - TradingView
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - accessnewswire.com
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - Corsicana Daily Sun
CNS Pharmaceuticals, Inc. Q2 2026: Net loss $2.59M, EPS $(0.38) — 10-Q Summary - TradingView
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - Yahoo Finance
CNS Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
CNSP Q1 2026 Earnings: Loss of $7.30 Per Share Misses Estimates as Pre-Revenue Pipeline Spend Rises - vinanet.vn
CNS Pharmaceuticals Inc (CNSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy
Supernus, Indivior Announce Merger to Create $2.2 Billion CNS - vohnetwork.com
Supernus and Indivior Agree to $2.2 Billion Revenue Merger to Create CNS Biopharma Leader - citybiz
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs - BioSpace
Supernus, Indivior merge to create CNS-focused company and expand BD opportunities - Fierce Pharma
Supernus Pharmaceuticals and Indivior Pharmaceuticals to - GlobeNewswire
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company - MedCity News
Cerenome Launches as an Integrated CNS Oncology Company - GlobeNewswire
Cerenome will combine CNS cancer diagnostics, treatments and AI Aug. 3 - Stock Titan
Cerenome Launches as an Integrated CNS Oncology Company - Yahoo Finance
CNS Pharmaceuticals Inc (CNSP) Cash Flow - TradingKey
CNS Pharmaceuticals Inc (CNSP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CNS Pharmaceuticals Inc (CNSP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNS Pharmaceuticals Inc (CNSP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
5.91%
2.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):